EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS
Аbstract. Сlinical and immunocorrective efficiency of Roncoleukin® (IL-2) monotherapy applied as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 m...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2014-07-01
|
| Series: | Медицинская иммунология |
| Subjects: | |
| Online Access: | https://www.mimmun.ru/mimmun/article/view/454 |
| _version_ | 1797198049622097920 |
|---|---|
| author | O. I. Zheltova N. M. Starostina M. A. Tikhonova O. Yu. Leplina E. R. Chernykh A. A. Ostanin |
| author_facet | O. I. Zheltova N. M. Starostina M. A. Tikhonova O. Yu. Leplina E. R. Chernykh A. A. Ostanin |
| author_sort | O. I. Zheltova |
| collection | DOAJ |
| description | Аbstract. Сlinical and immunocorrective efficiency of Roncoleukin® (IL-2) monotherapy applied as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 mg was accompanied by increased activity of Th1 lymphocytes and reduced in vitro production of IL-10, and does not exert any adverse immunotropic effects associated with Treg expansion. In general, the positive clinical effect was registered in 65% (26/40) of the patients, and its duration ranged between 3 and 7 months (a mean of 4.4±0.2 months). Clinical efficiency of Roncoleukin® inhalations proved to be not inferior to conventional Roncoleukin® immunotherapy performed by subcutaneous injections (resp., 70 and 60% of positive responses), and allows a more significant prolongation of event-free remission. (Med. Immunol., 2011, vol. 13, N 2-3, pp 227-236) |
| first_indexed | 2024-03-08T05:51:06Z |
| format | Article |
| id | doaj.art-cff50ac638bf4de78a946b0819458c87 |
| institution | Directory Open Access Journal |
| issn | 1563-0625 2313-741X |
| language | Russian |
| last_indexed | 2024-04-24T06:53:41Z |
| publishDate | 2014-07-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj.art-cff50ac638bf4de78a946b0819458c872024-04-22T13:07:37ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2014-07-01132-322723610.15789/1563-0625-2011-2-3-227-236451EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONSO. I. Zheltova0N. M. Starostina1M. A. Tikhonova2O. Yu. Leplina3E. R. Chernykh4A. A. Ostanin5НИИ клинической иммунологии СО РАМН, г. НовосибирскНИИ клинической иммунологии СО РАМН, г. НовосибирскНИИ клинической иммунологии СО РАМН, г. НовосибирскНИИ клинической иммунологии СО РАМН, г. НовосибирскНИИ клинической иммунологии СО РАМН, г. НовосибирскНИИ клинической иммунологии СО РАМН, г. НовосибирскАbstract. Сlinical and immunocorrective efficiency of Roncoleukin® (IL-2) monotherapy applied as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 mg was accompanied by increased activity of Th1 lymphocytes and reduced in vitro production of IL-10, and does not exert any adverse immunotropic effects associated with Treg expansion. In general, the positive clinical effect was registered in 65% (26/40) of the patients, and its duration ranged between 3 and 7 months (a mean of 4.4±0.2 months). Clinical efficiency of Roncoleukin® inhalations proved to be not inferior to conventional Roncoleukin® immunotherapy performed by subcutaneous injections (resp., 70 and 60% of positive responses), and allows a more significant prolongation of event-free remission. (Med. Immunol., 2011, vol. 13, N 2-3, pp 227-236)https://www.mimmun.ru/mimmun/article/view/454cytokine balanceregulatory t-cellscytokine therapyil-2recurrent infections |
| spellingShingle | O. I. Zheltova N. M. Starostina M. A. Tikhonova O. Yu. Leplina E. R. Chernykh A. A. Ostanin EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS Медицинская иммунология cytokine balance regulatory t-cells cytokine therapy il-2 recurrent infections |
| title | EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS |
| title_full | EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS |
| title_fullStr | EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS |
| title_full_unstemmed | EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS |
| title_short | EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS |
| title_sort | efficiency of roncoleukin r in treatment of chronic recurrent infections |
| topic | cytokine balance regulatory t-cells cytokine therapy il-2 recurrent infections |
| url | https://www.mimmun.ru/mimmun/article/view/454 |
| work_keys_str_mv | AT oizheltova efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT nmstarostina efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT matikhonova efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT oyuleplina efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT erchernykh efficiencyofroncoleukinintreatmentofchronicrecurrentinfections AT aaostanin efficiencyofroncoleukinintreatmentofchronicrecurrentinfections |